Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2010

01-11-2010 | Original Article

Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait

Authors: Waleed M. Alazmi, Waleed Buhaimed, Khalid Al-Mekhaizeem, Iqbal Siddique

Published in: Digestive Diseases and Sciences | Issue 11/2010

Login to get access

Abstract

Introduction

Recent studies suggest that the initial treatment success rates for H. pylori infection are falling below 80% in many parts of the world.

Aim

The aim of this study was to evaluate the efficacy of standard triple therapy in the treatment of H. pylori infection in Kuwait.

Methods

Consecutive H. pylori positive patients were enrolled in the study to receive clarithromycin, amoxicillin and omeprazole for 10 days. H. pylori status was checked with 13C urea breath test 6 weeks after the end of therapy. Endoscopic findings was recorded in all patients.

Results

One hundred forty-one patients (82 male and 59 females; mean age 41.8 years) were enrolled in the study. A total of seven patients were excluded from the per protocol analysis. The eradication rates in intention to treat (ITT) and per protocol (PP) were 72.3% (95% CI 64.2–79.5%) and 76.1% (95% CI 68–83%), respectively. The main endoscopic findings were normal in 47.5% and gastritis in 37.6%.

Conclusion

The efficacy of the current standard triple therapy for H. pylori eradication in our community is suboptimal. Confirmation for H. pylori eradication with noninvasive tests is recommended, especially in high-risk patients. New antimicrobial regimens for H. pylori eradication are considered necessary.
Literature
1.
go back to reference Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–1873.CrossRefPubMed Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–1873.CrossRefPubMed
2.
go back to reference Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht III consensus report. Gut. 2007;56:772–781.CrossRefPubMed Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht III consensus report. Gut. 2007;56:772–781.CrossRefPubMed
3.
go back to reference Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001.CrossRefPubMed Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology. 2007;133:985–1001.CrossRefPubMed
4.
go back to reference Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374.CrossRefPubMed Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374.CrossRefPubMed
5.
go back to reference Albert JM, Al-Mekhaizeem K, Neil L, et al. High prevalence and level of resistance of metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther. 2006;24:1359–1366.CrossRef Albert JM, Al-Mekhaizeem K, Neil L, et al. High prevalence and level of resistance of metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. Aliment Pharmacol Ther. 2006;24:1359–1366.CrossRef
6.
go back to reference De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period. J Antimicrob Chemother. 2007;59:783–785.CrossRefPubMed De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15-year period. J Antimicrob Chemother. 2007;59:783–785.CrossRefPubMed
7.
go back to reference Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMed Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med. 2002;136:13–24.PubMed
8.
go back to reference Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820–823.CrossRefPubMed Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820–823.CrossRefPubMed
9.
go back to reference Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306–309.CrossRefPubMed Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7:306–309.CrossRefPubMed
10.
go back to reference Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.CrossRefPubMed Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.CrossRefPubMed
11.
go back to reference Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1–12.CrossRefPubMed Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13:1–12.CrossRefPubMed
12.
go back to reference Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 2001;19:134–143.CrossRefPubMed Gisbert JP, Pajares JM. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 2001;19:134–143.CrossRefPubMed
Metadata
Title
Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait
Authors
Waleed M. Alazmi
Waleed Buhaimed
Khalid Al-Mekhaizeem
Iqbal Siddique
Publication date
01-11-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1139-z

Other articles of this Issue 11/2010

Digestive Diseases and Sciences 11/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.